SB-01injection The SB-01 peptide, also known by its investigational name Vicatertide, is a synthetic seven-amino acid peptide designed to target and modulate the activity of Transforming Growth Factor Beta (TGF-β)Vicatertide (SB-01) | TGF beta-1 Inhibitor. This cytokine plays a significant role in various biological processes, including inflammation and tissue repair.Introducing a synthetic 7-amino acid peptide Research has focused on SB-01's potential application in treating chronic low back pain, particularly that associated with degenerative disc disease (DDD). While clinical trials have explored its efficacy, understanding its mechanism of action, development status, and observed outcomes is crucial for evaluating its therapeutic promiseThe Phase 3 study of SB-01.
SB-01 functions as a TGF-β inhibitor, meaning it binds to and antagonizes the activity of this pleiotropic cytokine. TGF-β is implicated in the progression of DDD by promoting fibrotic changes and inflammation within the intervertebral discs. By down-regulating TGF-β signaling, SB-01 aims to reduce these pathological processes, thereby alleviating pain and potentially slowing disc degeneration. The peptide is administered via injection directly into the spinal disc, a targeted approach designed to deliver the therapeutic agent to the site of disease.
Developed by Spine BioPharma, SB-01 has undergone significant clinical investigation, including Phase III trials. The Spine BioPharma's Phase III MODEL trial assessed the safety and effectiveness of SB-01 for Injection in adult patients experiencing chronic low back pain and related disability due to DDD.Spine Takes Yuhan's Peptide Into US Phase III For High-Need ... While the trial aimed to confirm the safety and effectiveness of SB-01 for Injection, topline results released in August 2025 indicated that the study failed to achieve its primary endpoint.
Despite missing the primary goal, there have been reports suggesting that SB-01 demonstrated durable clinical improvements and consistent results in the Phase III MODEL trial.2022年4月13日—YH14618 (coded SB-01 by Spine) is a 7-amino acid chain peptide that binds to and induces down-regulation of transforming growth... Scrip ... Further analysis of the trial data is ongoing to fully understand the implications of these findings and the potential for SB-01 in managing DDD-related painVicatertide is a TGF beta-1 inhibitor. For research use only. We do not sell to patients. Custom Peptide Synthesis. Vicatertide Chemical .... The development of SB-01 also involved collaborations, such as the agreement with Ensol BioSciences to expand its development.
* Composition: SB-01 is a synthetic peptide composed of seven amino acids.
* Mechanism: It acts as a TGF-β inhibitor, binding to and antagonizing TGF-β activity.
* Target Condition: Primarily investigated for chronic low back pain associated with Degenerative Disc Disease (DDD)SB-01 is a synthetic 7-amino acid peptidethat binds to and induces down regulation of Transforming Growth Factor Beta 1 (TGFβ1)..
* Administration: Administered via injection into the spinal disc.
* Investigational Name: Vicatertide.
* Developer: Spine BioPharma.
While SB-01 is a specific research peptide, the broader field of peptide therapeutics continues to evolve. Other peptides, such as BPC-157, have also been explored for orthopedic and sports medicine applications, though their mechanisms and research focus differ from SB-01. It is important to distinguish SB-01 from other peptide research, such as SBP1, which involves fragments of ACE2, or MBP-B MHC II, related to myelin basic protein.
The outcome of the Phase III MODEL trial presents a complex picture for the future of SB-01. While it did not meet its primary objective, the reported durable clinical improvements warrant further investigation and discussion within the scientific and medical communities2025年8月4日—Spine BioPharma's Phase III MODEL trial assessing SB-01for people with CLBP associated with DDD failed to achieve its primary goal.. The journey of SB-01 highlights the challenges and complexities of developing novel treatments for conditions like DDD. Continued research and detailed analysis of the trial data will be essential in determining whether SB-01, or related TGF-β modulating peptides, can ultimately offer a viable therapeutic option for patients suffering from chronic low back pain.Spine BioPharma's TGF-β Antagonist Misses Primary ... The peptide's status as a potential first-in-class intradiscal pharmacologic treatment for DDD underscores the ongoing need for innovative approaches in pain management.2024年7月15日—SB-01 For Injection is a synthetic peptidecomposed of seven amino acids that antagonizes TGF-Beta, a cytokine found in almost all tissues ...
Join the newsletter to receive news, updates, new products and freebies in your inbox.